Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis

Published:2020-10 Issue:10 Volume:20 Page:e712-e723
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Bewersdorf Jan Philipp^ORCID,Giri Smith,Wang Rong^ORCID,Podoltsev Nikolai^ORCID,Williams Robert T.^ORCID,Rampal Raajit K.,Tallman Martin S.,Zeidan Amer M.,Stahl Maximilian

Funder

Boehringer Ingelheim

Astellas Pharma

Daiichi-Sankyo

Sunesis Pharmaceuticals

Jazz Pharmaceuticals

Pfizer

Astex Pharmaceuticals

CTI BioPharma

Celgene

Genentech

AI Therapeutics

Samus Therapeutics

Arog Pharmaceuticals

Kartos Therapeutics

AbbVie

Cellerant

Orsenix

ADC Therapeutics

Biosight

Incyte

Constellation

Stemline

Acceleron

Novartis

Otsuka

MedImmune

TrovaGene

Takeda

National Cancer Institute

National Institutes of Health

Memorial Sloan-Kettering Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference48 articles.

1. Philadelphia chromosome–negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet;Barbui;Leukemia,2018

2. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management;Tefferi;Am J Hematol,2018

3. Myelofibrosis biology and contemporary management [e-pub ahead of print];Gangat;Br J Haematol,2020

4. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms;Vainchenker;Blood,2017

5. How I treat myelofibrosis after failure of JAK inhibitors;Pardanani;Blood,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis;Annals of Hematology;2024-08-15

2. Interferons in the treatment of myeloproliferative neoplasms;Therapeutic Advances in Hematology;2024-01

3. SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera;Clinical Lymphoma Myeloma and Leukemia;2023-11

4. The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors;Expert Opinion on Pharmacotherapy;2023-06-26

5. Interferons in Myeloproliferative Neoplasms;Pathogenesis and Treatment of Leukemia;2023